Paycom Software Inc vs Viatris Inc — how do they compare? Paycom Software Inc trades at $214.7 (market cap $9.88B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| PAYC | VTRS | |
|---|---|---|
Market Cap | $9.88B | $19.09B |
Sector | Technology | Health |
52-Week High | $240.52 | $17.86 |
52-Week Low | $113.59 | $9.49 |
Enterprise Value | $10.66B | $31.21B |
Dividend Yield | 0.68% | 2.89% |
Signals from Pluang's Aura AI — not financial advice
Paycom Software (PAYC) trades at $219.16, down 5.4% today but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows a bullish technical signal despite recent weakness, supported by positive analyst sentiment and institutional accumulation. Recent Q2 2026 results exceeded expectations with EPS of $2.78 beating estimates of $2.38, driving management's raised full-year guidance.
Outlook remains positive with a consensus price target of $231.70 offering 5.7% upside potential. Key opportunities include sustained revenue growth and expanding margins, while risks involve competitive pressures and market volatility. The company's strong cash flow generation and shareholder returns through dividends and buybacks support long-term value creation.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Trailing returns across standard periods
Latest headlines on both assets
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →